Synthetic genomics, which is a major arm of synthetic biology, aims to create organisms harboring customized or tailor-made chromosomal sequences carrying desired genetic codes that confer novel functionalities. Due to astounding advances made in DNA synthesis technologies, the construction of designer synthetic genomes is becoming increasingly feasible, thus enabling deeper understanding of biological functions. At SynCTI, we are a part of the Synthetic Yeast 2.0 (Sc2.0) consortium working towards the construction of the first eukaryotic cell with a fully functional synthetic genome.
Genome-Wide Off-Target Detection
The use of CRISPR-based therapeutics for human applications is impeded by potential off-targeting effects, making the safety of these permanent genetic modifications a priority. As part of ongoing efforts to meet regulatory standards, significant emphasis is placed on accurate off-target detection. The development of enhanced predictive methods has been a focal point of various institutions, including pharmaceutical companies, universities, and regulatory bodies, to ensure the safe application of these technologies.
Invention of Novel Genome Editing Tools
Advancements in genome editing have expanded the CRISPR toolkit, allowing researchers to explore new possibilities and push the limits of genetic modification. Integrating diverse enzymes and techniques has led to the development of innovative tools with broad applications.
Optimization of Genome Editing Tools
The continuous refinement of genome editing tools is essential to their evolution into best-in-class technologies. Enhancing the specificity of these tools, without sacrificing activity, is a key focus for optimizing their therapeutic potential.
